Defining the disease course of TNFα blockers-associated Multiple Sclerosis
- Resource Type
- Authors
- Francesco Antonio Losavio; Assunta Bianco; Massimiliano Mirabella; Paolo Calabresi; Giorgia Presicce; Viviana Nociti; Chiara De Fino; Matteo Lucchini; Guido Maria Giuffré
- Source
- Subject
- Adult
Male
0301 basic medicine
Optic Neuritis
Immunology
Autoimmune Diseases
Disease course
Multiple sclerosis
03 medical and health sciences
Multiple Sclerosis, Relapsing-Remitting
0302 clinical medicine
medicine
TNFα
Humans
Immunologic Factors
Immunology and Allergy
Optic neuritis
Rheumatological disorders
Demyelinating disorders
Demyelinating Disorder
Central nervous system (CNS) inflammatory disorders
Retrospective Studies
Autoimmune disease
Tumor Necrosis Factor-alpha
business.industry
Middle Aged
medicine.disease
Tumour necrosis factor alpha blockers
Settore MED/26 - NEUROLOGIA
030104 developmental biology
Neurology
Concomitant
Cohort
Female
Tumor necrosis factor alpha
Neurology (clinical)
business
030217 neurology & neurosurgery
- Language
- English
Tumour Necrosis Factor alpha (TNFα) blockers are common and effective treatments for several autoimmune diseases but can be associated with neuroinflammatory events. We described the disease course of ten patients who developed CNS demyelinating events while exposed to TNFα blockers. We divided them into two groups: eight patients with Relapsing Multiple Sclerosis and two isolated optic neuritis. In our cohort, TNFα blockers-associated Multiple Sclerosis does not seem to be associated with a more aggressive course and can be managed with MS-specific DMTs, chosen considering the clinical course and the concomitant autoimmune disease. Our findings need confirmation in larger cohorts to further characterize the disease course of TNFα blockers-associated Multiple Sclerosis.